• Summit Therapeutics published an ASCO 2026 plenary presentation on Phase 3 HARMONi-6 in first-line advanced squamous NSCLC.
• Ivonescimab with carboplatin-paclitaxel met the prespecified interim overall survival endpoint versus tislelizumab with chemotherapy.
• Earlier interim results showed longer median PFS of 11.1 months versus 6.9 months; HR 0.6; p<0.0001.
• Trial enrolled 532 patients with stage IIIB-IV disease, ECOG 0-1, no prior systemic therapy, no EGFR or ALK alterations.
• Ivonescimab described as a PD-1/VEGF bispecific antibody, approved in China; investigational outside China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief on May 31, 2026, and is solely responsible for the information contained therein.